Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ribozyme Therapy
Phase I Clinical Trial For Breast/Ovarian Cancer Initiated
October 4th, 2001
Ribozyme Pharmaceuticals, Inc., (RPI) (RZYM) announced the start of a new Phase I clinical trial relating to the safety and pharmacokinetics of its innovative compound Herzyme. Herzyme is an anti-human epidermal growth factor receptor type 2 (HER2) ribozyme that is being developed through RPI's strategic collaboration with Elan Corporation (Medizyme Pharmaceuticals, Ltd.). Elan and RPI are planning to develop Herzyme for treatment of breast and ovarian cancer in conjunction with Elan's proprietary Medipad Drug Delivery system. "The initiation of this trial in conjunction with our partner Elan, marks another key step toward development of...
Source: Women's Health Weekly (2001-10-04)
|
